Happening now at #GI26: “Rapid Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract” chaired by Dr. Arndt Vogel. #pancsm #hpbcsm

meetings.asco.org/meetings/202...

We’re in for an engaging hour with an international & multidisciplinary hepatobiliary tumor board tackling complex HCC cases during the #GI26 “Liver Power Hour” chaired by Dr. Riad Salem & Dr. Nina Niu Sanford. #hpbcsm

meetings.asco.org/meetings/202...

@lorenzarimassa.bsky.social

Getting the latest research into cancers of the pancreas, small bowel & hepatobiliary tract at #GI26 Oral Abstract Session B chaired by Dr Neehar Parikh & Dr Myriam Chalabi following a welcome & Meetings App poll feature warm-up from Dr David Wang. #pancsm #hpbcsm meetings.asco.org/meetings/202...

The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers Hepatobiliary malignancies represent a growing global health burden, with rising incidence rates worldwide [1–3]; however, recent years have witnessed remarkable therapeutic breakthroughs that are res...

A a high yield #GIonc review of #IO agents in #hpbcsm

#IO has transformed treatment, ⬆️ #OS and creating new #SoC.

💉 Reviews #regimens
🤝 Discusses #synergy with chemo
🚧 Highlight unmet #needs

🔗: cancertreatmentreviews.com/article/S030...

@oncoalert.bsky.social
@weoncologists.bsky.social

Zanidatamab Wins Approval in China for Previously Treated, HER2+ Biliary Tract Cancer
#BiliaryTractCancer #hpbcsm
www.onclive.com/view/zanidat...

Tovecimig Plus Paclitaxel Meets ORR End Point in Second-Line Biliary Tract Cancer Tovecimig plus paclitaxel improved overall response rate vs paclitaxel alone in second-line advanced biliary tract cancer.

Tovecimig Plus Paclitaxel Meets ORR End Point in Second-Line Biliary Tract Cancer
#hpbcsm #Oncology
www.onclive.com/view/tovecim...

SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors SAR444200-mediated targeting of GPC3-expressing solid tumors was safe and showed early signs of antitumor activity in a phase 1/2 study.

SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors
@myesmo.bsky.social #hpbcsm #oncology
www.onclive.com/view/sar4442...

FDA Grants Fast Track Designation to Amezalpat for Hepatocellular Carcinoma The FDA has granted fast track designation to amezalpat for patients with hepatocellular carcinoma.

The @fda.gov Grants Fast Track Designation to Amezalpat for Hepatocellular Carcinoma
#hpbcsm #FDA #oncology
www.onclive.com/view/fda-gra...

Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options [Mar 30, 2020] Bitzer et al. @ASCO_pubs ow.ly/MuHP30qAEI0 #PrecisionMedicine #ancsm #crcsm #esocsm #hpbcsm #pancsm #sbcsm #stcsm n=96, Apr 2016 - Feb 2018